A biopharmaceutical company with a novel treatment of chronic kidney disease-associated pruritus asked L.E.K. to assess the potential risk of bundling of the therapy within the dialysis tariff and to develop mitigating strategies against this risk.

L.E.K.’s approach

Our case team developed an understanding of the hemodialysis and CKD-aP treatment reimbursement landscape in relevant European markets and identified those markets where the product is at risk of being included in the dialysis reimbursement bundle. We assessed the key dynamics for decision-making in at-risk markets and identified potential levers to ensure sufficient funding. In collaboration with local teams of at-risk markets, we prioritized key levers to include in country funding strategies and developed local tactics and stakeholder engagement plans for implementing the country strategy.  

Value delivered to the client

L.E.K. Consulting is a registered trademark of L.E.K. Consulting LLC. All other products and brands mentioned in this document are properties of their respective owners. © 2024 L.E.K. Consulting LLC

Value Story and Cross-Stakeholder Action Plan for Oncology Reimbursement
business meeting with healthcare professionals
See how L.E.K. supported a big pharma company with fostering change in payer attitudes to increase acceptance of patient-reported outcomes (PROS).

Related Insights